Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared on X:
“Just out!
In NEJM – Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!
Implications are huge. This is a drug we spends billions on each year:
- Less side effects
- Less second cancers
- Similar overall survival
- Less cost
National NCI funded trial led by ECOG-ACRIN Cancer Research Group and joined by Alliance for Clinical Trials in Oncology and SWOG Cancer Research Network”
To which Murali Janakiram, Associate Professor at the Division of Hematological Malignancies, Myeloma, Cellular Immunotherapy and Immune Checkpoints at City of Hope, added:
“Wow…
What a trial and the effort. This is so important in our field where the practice has been indefinite maintenance…. This is very relevant to clinical practice today.. Gratt work, Vincent Rajkumar and Shaji Kumar.
The next trial to read will be risk adapted maintenance by Amrita Krishnan., SWOG1803.
Thanks to ECOG-ACRIN Cancer Research Group and Anthony Letai for funding.”
Hira Mian, Multiple Myeloma Lead at Hamilton Health Science, also added:
“ALERT: Major MM therapy paradigm shift with ENDURANCE trial showing less therapy as good as indefinite therapy.
On behalf of patients and clinicians, thank you for doing this study.”
Raj Chakraborty, Hematologist, Oncologist, Clinical Researcher at Herbert Irving Comprehensive Cancer Center, and Assistant Professor at Columbia University Irving Medical Center, also shared his opinion on X:
“This is huge and has so many implications!
Indefinite Len maintenance until progression is dead!”
Hira Mian also added to Raj Chakraborty’s post:
“Raj, you have said it the best! Indefinite Len is dead and future trials need to change more broadly to evaluate shorter duration of treatments. MM treatment is underoing a paradigm shift- the Master Luciano J Costa and ENDURANCE trial with Shaji Kumar and Vincent Rajkumar show its possible.”
Title: Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Authors: Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S. Vincent Rajkumar.
Other articles about Myeloma on OncoDaily.